TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16192591

Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m² and Docetaxel 75 mg/m² (AT)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Fluorouracil 500 mg/m², Doxorubicin 50 mg/m², and Cyclophosphamide 500 mg/m² (FAC)
Number of subjects: 216
Study: 12047485

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (0.7 mg kg(‐1))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketamine (0.375 mg kg(‐1))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10091823

Group type: EXPERIMENTAL
Intervention: Amiodarone (300 mg intravenously over 1 h, followed by 20 mg/kg over the next 24 h plus 600 mg orally, in three doses, for 1 week, then 400 mg/day orally, for three weeks)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Propafenone (2 mg/kg intravenously over 15 min, followed by 10 mg/kg over 24 h and then 450 mg/day orally, for one month)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 101
Study: 8543508

Group type: EXPERIMENTAL
Intervention: Therapy for sexually abused children
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Therapy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Future sexual abuse therapy outcome research considerations
Number of subjects: 29
Study: 2407764

Group type: EXPERIMENTAL
Intervention: Ornithine alpha-ketoglutarate (OKG) 10 g (3.6 g alpha KG and 6.4 g ORN)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ornithine hydrochloride 6.4 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Calcium alpha-ketoglutarate 3.6 g
Number of subjects: 6
Study: 373415

Group type: EXPERIMENTAL
Intervention: L-Histidine, 4 g/day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7109499

Group type: EXPERIMENTAL
Intervention: VAC/FMC plus 5 mg/m2 Corynebacterium parvum (CP) subcutaneously on day 1
Number of subjects: 156

Group type: COMPARATOR
Intervention: VAC/FMC
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: VAC/FMC plus CP
Number of subjects: 156
Study: 30917820

Group type: COMPARATOR
Intervention: Checklist (CL)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Group (G)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Student Tutor (ST)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Teacher (T)
Number of subjects: 64
Study: 30448170

Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Uncoated Balloon (PTA)
Number of subjects: 200
Study: 27346756

Group type: EXPERIMENTAL
Intervention: Experimental intervention (usual care + WHO's contraception initiation protocol + financial incentives)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care (condoms, emergency contraception, referral to local providers)
Number of subjects: 31
Study: 25149596

Group type: EXPERIMENTAL
Intervention: 50mg ipragliflozin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100mg ipragliflozin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21822934

Group type: EXPERIMENTAL
Intervention: Intravenous 10% caprylate-chromatography purified immunoglobulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19348602

Group type: EXPERIMENTAL
Intervention: Bromfenac sodium (BF) 0.1% ophthalmic solution with disodium cromoglycate (DSCG) 2.0%
Number of subjects: 86

Group type: COMPARATOR
Intervention: Fluorometholone (FML) 0.02% ophthalmic suspension with disodium cromoglycate (DSCG) 2.0%
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Patient preference for concomitant treatment
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Patient's global evaluation
Number of subjects: 86
Study: 17472472

Group type: EXPERIMENTAL
Intervention: Seaweed (Alaria esculenta), 5 g/day for 7 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Soy protein isolate, 141.3 mg of isoflavones/day for the last week of each treatment arm
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo, 5 g/day for 7 weeks
Number of subjects: 25
Study: 16007329

Group type: EXPERIMENTAL
Intervention: Regular sunlight exposure (3615 minutes/year)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Sunlight deprivation
Number of subjects: 264
Study: 11981081

Group type: EXPERIMENTAL
Intervention: Fish oil (6 g/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Soy oil (control)
Number of subjects: 86
Study: 10512898

Group type: EXPERIMENTAL
Intervention: Risk factors including blood pressure, blood cholesterol, glucose, respiratory function, cardiothoracic ratio, smoking habit, height, body mass index, age, preexisting coronary heart disease, and diabetes.
Number of subjects: 15406

Group type: EXPERIMENTAL
Intervention: Glucose levels in nondiabetics.
Number of subjects: 15406

Group type: COMPARATOR
Intervention: Former smokers.
Number of subjects: 15406

Group type: EXPERIMENTAL
Intervention: Sex-specific multivariate models.
Number of subjects: 15406
Study: 7726397

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 6 mg.kg‐1.h‐1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 12 mg.kg‐1.h‐1
Number of subjects: 18
Study: 2074175

Group type: EXPERIMENTAL
Intervention: Surgical treatment for restoration of venous patency and valvular function
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conservative treatment with heparin, oral anticoagulants, and compression stockings
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Surgical treatment for ilio-femoral DVT
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conservative treatment for ilio-femoral DVT
Number of subjects: 49
Study: 7004557

Group type: EXPERIMENTAL
Intervention: Op-Site Skin Closure
Number of subjects: 110

Group type: COMPARATOR
Intervention: Interrupted nylon sutures
Number of subjects: 110

Group type: COMPARATOR
Intervention: Michel clips
Number of subjects: 110
Study: 31870935

Group type: EXPERIMENTAL
Intervention: Breakfast consumption
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (1.2g·min‐1 glucose)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Breakfast omission
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 23
Study: 31424243

Group type: EXPERIMENTAL
Intervention: Graphic health warning posters (GWPs) displayed near the check-out area (n = 334)
Number of subjects: 441

Group type: COMPARATOR
Intervention: No graphic health warning posters (status quo; n = 107)
Number of subjects: 441
Study: 28114650

Group type: COMPARATOR
Intervention: Beach umbrella
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Sunscreen with SPF 100
Number of subjects: 81
Study: 25828648

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine delivered with the Tx360 device
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 41
Study: 23743741

Group type: EXPERIMENTAL
Intervention: SUS Group
Number of subjects: 174

Group type: COMPARATOR
Intervention: Streamline Group
Number of subjects: 174
Study: 20842109

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg, vitamin C 1 g, and vitamin E 1,000 IU
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 1005
Study: 19959730

Group type: EXPERIMENTAL
Intervention: Feedback in the form of video playback of driving performance
Number of subjects: 30

Group type: COMPARATOR
Intervention: No feedback (Control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Secondary mobile phone task during driving simulation
Number of subjects: 30
Study: 17650804

Group type: EXPERIMENTAL
Intervention: Jiangzhuo Huoxue Yishen Decoction (JHYD) combined with Finbid and allopurinol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Finbid and allopurinol (Control)
Number of subjects: 90
Study: 15565596

Group type: EXPERIMENTAL
Intervention: Surgery plus preoperative treatment with recombinant human IL‐2 (34 patients)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Surgery alone (35 patients)
Number of subjects: 69
Study: 12445025

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg orally each morning (07.00 h)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg orally each evening (18.00 h)
Number of subjects: 24
Study: 10662482

Group type: EXPERIMENTAL
Intervention: Coformulation of low dose aspirin plus modified-release dipyridamole
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Modified-release dipyridamole
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No antiplatelet therapy
Number of subjects: 1000
Study: 7474243

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 2652) received estimates of likelihood of 6-month survival, outcomes of CPR, and functional disability at 2 months; a trained nurse facilitated communication and advance care planning.
Number of subjects: 9105

Group type: COMPARATOR
Intervention: Control group (n = 2152)
Number of subjects: 9105
Study: 2304776

Group type: EXPERIMENTAL
Intervention: Cyclosporine A treatment for 4 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cyclosporine A treatment
Number of subjects: 43
Study: 6775296

Group type: EXPERIMENTAL
Intervention: isosorbide dinitrate (ID) 5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: nitroglycerin microcapsules (NGMC) 7.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: pentaerythritol tetranitrate (PETN) 160 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 30496299

Group type: EXPERIMENTAL
Intervention: HIV‐DNA intradermal priming regimens (Group I: 2x0.1mL [3mg/mL], Group II: 2x0.1mL [3mg/mL] plus electroporation, Group III: 1x0.1mL [6mg/mL] plus electroporation)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: HIV‐MVA administered with or without CN54rgp140/GLA‐AF
Number of subjects: 191

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 191
Study: 26399404

Group type: EXPERIMENTAL
Intervention: Bedtime ingestion of hypertension medications
Number of subjects: 2012

Group type: COMPARATOR
Intervention: Morning ingestion of hypertension medications
Number of subjects: 2012
Study: 24788781

Group type: EXPERIMENTAL
Intervention: Monthly household food basket (FB) plus nutrition education (NE)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Nutrition education (NE) alone
Number of subjects: 400
Study: 23071212

Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg daily)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 20196651

Group type: EXPERIMENTAL
Intervention: Microbiologic TB test
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: History of TB treatment
Number of subjects: 584

Group type: COMPARATOR
Intervention: Smear technique
Number of subjects: 584
Study: 19137863

Group type: EXPERIMENTAL
Intervention: Topical anesthesia (tetracaine 0.5% eye drops and preservative free lidocaine 2% intracamerally)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Retrobulbar anesthesia (4 mL lidocaine 2% into the retrobulbar space)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Both groups (Topical and Retrobulbar)
Number of subjects: 564
Study: 15771597

Group type: EXPERIMENTAL
Intervention: Prostaglandin therapy
Number of subjects: 14
Study: 12466572

Group type: EXPERIMENTAL
Intervention: Deworming (anthelmintics)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 10760336

Group type: EXPERIMENTAL
Intervention: Low-fat vegetarian diet (10% of energy from fat) for 2 menstrual cycles
Number of subjects: 35

Group type: COMPARATOR
Intervention: Customary diet with placebo pill for 2 menstrual cycles
Number of subjects: 35
Study: 8558188

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 800 mg/d orally
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 1829865

Group type: EXPERIMENTAL
Intervention: Salbutamol 400 micrograms
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 80 micrograms
Number of subjects: 188
Study: 6407453

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol and Diltiazem (combined)
Number of subjects: 10
Study: 31637972

Group type: EXPERIMENTAL
Intervention: EXTRAS
Number of subjects: 573

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 573
Study: 27638452

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (not specified dosage or duration)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Consenting patients (control group)
Number of subjects: 560
Study: 26759155

Group type: EXPERIMENTAL
Intervention: Aerobic training (12-week duration)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (non-training)
Number of subjects: 16
Study: 24841866

Group type: EXPERIMENTAL
Intervention: Family Behavior Therapy (FBT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 72
Study: 23197280

Group type: EXPERIMENTAL
Intervention: Exercise group (EG, n=91)
Number of subjects: 169
Study: 20613691

Group type: EXPERIMENTAL
Intervention: Earplugs (PLUG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No earplugs (noPLUG)
Number of subjects: 100
Study: 17617527

Group type: EXPERIMENTAL
Intervention: Weekly intravenous cisplatin at 40 mg/m2 for 6 weeks in combination with radiation therapy (RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 0
Study: 16228060

Group type: EXPERIMENTAL
Intervention: Ketoconazole (KCZ) administered during the stimulation phase to 28 patients.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group of 30 patients not receiving KCZ.
Number of subjects: 58
Study: 11871848

Group type: EXPERIMENTAL
Intervention: Intensive ergonomics
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Ergonomic education
Number of subjects: 124

Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 124
Study: 10217001

Group type: EXPERIMENTAL
Intervention: Closed suction drainage removed after 12 hours
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Closed suction drainage removed after 24 hours
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Closed suction drainage removed after 48 hours
Number of subjects: 3
Study: 7674882

Group type: EXPERIMENTAL
Intervention: Thermoneutral water (TW) at 50 W for 40 rev.min‐1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Thermoneutral water (TW) at 100 W for 40 rev.min‐1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Thermoneutral air (TA) at 50 W for 40 rev.min‐1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Thermoneutral air (TA) at 50 W for 50 rev.min‐1
Number of subjects: 9
Study: 8245329

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes
Number of subjects: 11667

Group type: EXPERIMENTAL
Intervention: Noninsulin-dependent diabetes
Number of subjects: 11667

Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 11667

Group type: EXPERIMENTAL
Intervention: Overall mortality risk
Number of subjects: 11667

Group type: EXPERIMENTAL
Intervention: Post-discharge prognosis
Number of subjects: 11667
Study: 3516396

Group type: COMPARATOR
Intervention: 5-FU and carmustine (FB)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 5-FU, carmustine, and doxorubicin (FAB)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Partial remission
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: No change
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Progressive disease
Number of subjects: 77
Study: 30613055

Group type: EXPERIMENTAL
Intervention: Integrated psychoeducational program (individual face-to-face education and telephone-delivered health-coaching sessions)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Integrated psychoeducational program
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 47
Study: 27062538

Group type: EXPERIMENTAL
Intervention: Alcohol mixed with energy drink (AMED)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Alcohol only (AO)
Number of subjects: 56
Study: 25013089

Group type: EXPERIMENTAL
Intervention: Primary PCI with distal protection
Number of subjects: 591

Group type: COMPARATOR
Intervention: Primary PCI without distal protection
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Standard PCI with DE
Number of subjects: 591

Group type: COMPARATOR
Intervention: Standard PCI without DE
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Distal protection with DE
Number of subjects: 591

Group type: COMPARATOR
Intervention: Distal protection without DE
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Standard PCI
Number of subjects: 591
Study: 24511648

Group type: EXPERIMENTAL
Intervention: ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure (Group A)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure (Group B)
Number of subjects: 94

Group type: COMPARATOR
Intervention: ACE/ARB continued throughout the study period (Group C)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Patients with baseline eGFR < 60 ml/min (Intervention vs Control)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Patients with baseline eGFR >= 60 ml/min (Intervention vs Control)
Number of subjects: 94
Study: 21700760

Group type: EXPERIMENTAL
Intervention: Multimodal nutritional rehabilitation (health education, oral nutritional supplements, exercise, oral testosterone) for 90 days
Number of subjects: 122

Group type: COMPARATOR
Intervention: Home health education (control group)
Number of subjects: 122
Study: 18347680

Group type: EXPERIMENTAL
Intervention: Quercetin (1000 mg daily for 6 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (1000 mg daily for 6 weeks)
Number of subjects: 40
Study: 17135813

Group type: EXPERIMENTAL
Intervention: Community involvement group (n=207)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Self-improvement group (n=210)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Non-participants (n=211)
Number of subjects: 628
Study: 12937043

Group type: EXPERIMENTAL
Intervention: Cocaine exposure
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Opiate exposure
Number of subjects: 1

Group type: COMPARATOR
Intervention: Matched comparison infants
Number of subjects: 1
Study: 10685535

Group type: EXPERIMENTAL
Intervention: Cetrorelix (3 mg single dose)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Triptorelin (control)
Number of subjects: 154
Study: 9564716

Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention for 1 year
Number of subjects: 209
Study: 10147230

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 3174724

Group type: EXPERIMENTAL
Intervention: 15 g fructose-1,6-diphosphate (FDP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 7.5 g dextrose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study: 29904824

Group type: EXPERIMENTAL
Intervention: Monthly minodronate 50 mg every 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly alendronate or risedronate
Number of subjects: 0
Study: 26779704

Group type: EXPERIMENTAL
Intervention: Training program 'Active and safe with wheeled walkers' for 10 weeks (90 min, twice a week)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (15 persons)
Number of subjects: 28
Study: 24884497

Group type: EXPERIMENTAL
Intervention: Four Pillars Approach
Number of subjects: 360
Study: 23175340

Group type: EXPERIMENTAL
Intervention: IL‐2
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: IFN‐γ
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 66
Study: 21033156

Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol wash (A group)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Water wash (B group)
Number of subjects: 37
Study: 18158496

Group type: EXPERIMENTAL
Intervention: Home health nursing services
Number of subjects: 0
Study: 15809565

Group type: EXPERIMENTAL
Intervention: Baseline load (BSLN) condition, mean of 2.0 kg per leg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Load condition with a mean of 2.0 kg per leg, increased moment of inertia (MOI5)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Load condition with a mean of 2.8 kg per leg, increased total lower-extremity mass (Mass5)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No load (NL)
Number of subjects: 14
Study: 12459670

Group type: EXPERIMENTAL
Intervention: Salbutamol pretreatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lidocaine inhalation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dyclonine inhalation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lidocaine with Salbutamol pretreatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dyclonine
Number of subjects: 10
Study: 8877291

Group type: EXPERIMENTAL
Intervention: NDDG criteria
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: WHO criteria
Number of subjects: 709
Study: 2679258

Group type: EXPERIMENTAL
Intervention: BCG vaccination within the first 7 days of life
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: BCG vaccination before 9 months
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: BCG vaccination between 9 months and 2 years
Number of subjects: 184

Group type: COMPARATOR
Intervention: No BCG vaccination
Number of subjects: 184
Study: 1105502

Group type: EXPERIMENTAL
Intervention: 100 μg of salmefamol given by metered aerosol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Subcutaneous adrenaline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Subcutaneous atropine
Number of subjects: 24
Study: 31826336

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (540,000 IU single enteral dose)
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Placebo (matched placebo)
Number of subjects: 1078
Study: 27790824

Group type: EXPERIMENTAL
Intervention: G‐CSF combined with intramyocardial (i.m.) injection of autologous bone marrow-derived cells (BMCs)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (saline only)
Number of subjects: 90

Group type: COMPARATOR
Intervention: G‐CSF with intracoronary (i.c.) injection of BMCs or serum (placebo)
Number of subjects: 90

Group type: COMPARATOR
Intervention: G‐CSF with peripheral placebo (saline only)
Number of subjects: 90